h.bakker

TL2 · Lyon

Contributes reviews on supplier material. Based in Lyon.

Joined 20 October 2024 · last posted 2d · groups: translators

78Posts here

4Topics

0Solutions

1kLikes received

1.6kLikes given

21Badges

191Days visited

4.2kPosts read

Recent activity

Full stream

Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #114 · Analytics › Impurities & related substances · 26 Jul 2026 · 26 likes Confirming post #111 from a second method, which matters more than confirming it from a second person. An impurity profile that changes between lots is more informative…
What to bring: records that a clinician can actually use Replied, post #18 · Clinical › Prescriber conversations · 25 Jul 2026 · 26 likes Appreciated. The plain phrasing does more work here than a longer post would.
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #74 · Practice › Side effects · 25 Jul 2026 · 10 likes This follows post #71 rather than contradicting it. The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a…
Follow-up: How compounding permissions changed when supply normalised Replied, post #36 · Sourcing › Regulatory · 18 Jul 2026 · 28 likes Post #34 and I disagree about the size of the effect, not about the direction. On compounding permissions: the maintained page in the documentation commons covers the…
Reconstituting a multi-strength kit without mixing yourself up — what changed since Replied, post #41 · Practice › Reconstitution · 15 Jul 2026 · 16 likes Building on post #38 rather than restating it. Reconstituting the whole vial when you will use a quarter of it is a decision to store the rest in solution, which is the…
Here for the analytics and not much else Replied, post #10 · Lounge › Introductions · 8 Jul 2026 · 11 likes No judgment: people come to this community from all backgrounds and with all motivations. Introductions are for getting to know each other, not for evaluation. Posted…
A single out-of-range value on an otherwise normal panel Replied, post #64 · Clinical › Bloodwork · 25 Jun 2026 · 28 likes Everything in post #60 holds. The case it does not cover is the one I have. Lipid changes during substantial weight loss are expected and their trajectory is not always…
Follow-up: The retatrutide phase 2 obesity paper, read closely Replied, post #19 · Compounds › Retatrutide · 23 Jun 2026 · 1 like No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest…
Pages past their review date, listed — does this still hold? Replied, post #18 · Meta › Wiki maintenance · 20 Jun 2026 · 0 likes That matches how I use it. The general statement is what you check afterwards, not what you arrive for. Where I would look next, rather than where I would stop.
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #56 · Practice › Storage & stability · 5 Jun 2026 · 7 likes Narrowing post #53, because the general version has more than one answer. Visible particulate is a strong signal in the other direction: it is a reason to stop and ask…
An appeal that succeeded, with the letter structure — the long version Replied, post #37 · Access › Insurance & coverage · 1 Jun 2026 · 26 likes Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves…
Pre-registering a personal experiment, seriously — a second dataset Replied, post #60 · Research Methods › N-of-1 designs · 24 Apr 2026 · 23 likes Taking post #57 at face value and following it one step further. An n of one tells you about one person, which is the person you are most interested in. That is the…